In this episode, healthcare analyst Dr Arron Aatkar provides an overview of the Biotech Growth Trust, the London-listed investment company that seeks capital appreciation by investing in the worldwide biotechnology industry. He discusses the stock selection process, which involves a bottom-up approach, and comments on how the trust favours smaller, emerging biotechs. He also provides an overview of the current portfolio, highlighting the notable increase in exposure to Chinese biotechs during the first half of 2025. The discussion then moves on to the trust's performance in recent years, from the highs seen across the sector during the COVID-19 pandemic to the flight of capital and rightsizing. He concludes with the managers' outlook on the healthcare sector, commenting on how the current landscape may be perceived as a compelling mix of attractive valuations and increasing demand for new biotech innovations.***********************************************************About ‘Uncovering Trusts’'Uncovering Trusts': is a podcast run by Edison analysts released every two weeks. Subscribe to hear analyst interviews on how investment trusts maximise returns while managing risks for investors.About Edison:Edison is a content-led IR business. We believe quality investment content should inform all investors, not just brokers. Our mission: engage and build bigger, better-informed investor audiences for our clients.Edison covers 50+ investment trusts, read about them here: https://www.edisongroup.com/equities/investment-companies/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related